Selegiline in the treatment of Alzheimer's disease: A long-term randomized placebo-controlled trial

Journal of Psychiatry and Neuroscience

Volumn 24, Issue 3, 1999, Pages 234-243

  Filip, Václav ^a,c   Kolibás, Eduard ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

^b Physics and Informatics   (Slovakia)

^c Knoll s ro   (Czech Republic)

Author keywords

Aged; Alzheimer disease; Cognition; Dementia; Monoamine oxidase inhibitors; Nootropic agents; Selegiline

Indexed keywords

DOPAMINE RECEPTOR; SELEGILINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; ELECTROENCEPHALOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPROTECTION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MEMORY DISORDERS; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; SELEGILINE;

EID: 0032999243     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Gottfries CD. Multiple biochemical disturbances in brains from patients with Alzheimer dementia. N Trends Aging Res 1988;15:165-75.
2. Danielczyk W, Striefler M, Konradi C, et al. Platelet MAO-B activity and the psychopathology of Parkinson's disease, senile dementia and multi-infarct dementia. Acta Psychiatr Scand 1988;78:730-6.
3. Sunderland T, Tariot PN, Cohen RM, et al. Dose-dependent effects of deprenyl on CFS monoamine metabolites in patients with Alzheimer's disease. Psychopharmacology 1987;91: 293-6.
4. Knoll J. The striatal dopamine dependency of life span in male rats. Longevity study with /-/ deprenyl. Mech Ageing Dev 1988;46:237-62.
5. Wu RM, Mohanakumar KP, Murphy DL, Chiueh CC. Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline). Ann N Y Acad Sci 1994;738:214-21.
6. de la Cruz CP, Revilla E, Steffen V, Rodriguez Gomez JA, Cano J, Machado A. Protection of the aged substantia nigra of the rat against oxidative damage by (-)-deprenyl. Br J Pharmacol 1996;117(8):1756-60.
7. Mytilineou C, Radcliffe P, Leonardi EK, Werner P, Olanow CW, L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. J Neurochem 1997;68(1):33-9.
8. Salo PT, Tatton WG. Deprenyl reduces the death of motoneurons caused by axotomy. J Neurosci Res 1992;31(2):394-400.
9. Iwasaki Y, Ikeda K, Shiojima T, Kobayashi T, Tagaya A, Kinoshita M. Deprenyl enhances neurite outgrowth in cultured spinal ventral horn neurons. J Neurol Sci 1994;125(1):11-3.
10. Tatton WG, Chalmers-Redman RM. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology 1996;47(6 Suppl 3): 5171-83.
11. Muller T, Kuhn W, Kruger R, Przuntek H. Selegiline as immunostimulant - a novel mechanism of action? J Neural Transm Suppl 1998;52:321-8.
12. Stoll S, Hafner U, Pohl O, Muller WE. Age-related memory decline and longevity under treatment with selegiline. Life Sci 1994;55(25-26):2155-63.
13. Martini E, Szilagiy K, Venter V. Brief information on a early phase-II-study with deprenyl in demented patients. Pharmacopsychiatria 1987;20:256-7.
14. Tariot PN, Cohen RM, Sunderland T, et al. 1-Deprenyl in Alzheimer's disease. Arch Gen Psychiatry 1987;44:427-33.
15. Piccinin GL, Finali G, Piccirilli M. Neuropsychological effects of L-deprenyl in Alzheimer's type dementia. Clin Neuropharmacol 1990;13(2):147-163.
16. Mangoni A, Grassi MP, Frattola L, Piolti R, Bassi S, Motta A, et al. Effects of a MAO-B inhibitor in the treatment of Alzheimer disease. Eur Neurol 1991;31:100-7.
17. Schneider LS, Olin JT, Pawluczyk S, A double-blind crossover pilot study of 1-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease. Am J Psychiatry 1993;150(2):321-3.
18. Lawlor BA, Aisen PS, Green C, Fine K, Schmeidler J. Selegiline in the treatment of behavioral disturbance in Alzheimer's disease. Int J Geriatr Psychiatry 1997;12(3):319-22.
19. Burke WJ, Roccaforte WH, Wengel SP, Bayer BL, Ranno AE, Willcockson NK. L-deprcnyl in the treatment in mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc 1993;41:1219-25.
20. Freedman M, Rewilak D, Xerri T, Cohen S, Gordon AS, Shandling M, et al. L-deprenyl in Alzheimer's disease: cognitive and behavioral effects. Neurology 1998;50(3):660-8.
21. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheirner's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997; 336(17):1216-22.
22. Ashford JW, Kolm P, Colliver JA, Bekian C, Hsu LN. Alzheimer patient evaluation and the Mini Mental-State: item characteristic curve analysis. J Gerontal 1989;44(5):139-46.
23. Wolf-Klein GP, Silverstone FA, Levy AP, Brod MS. Screening for Alzheimer's disease by clock drawing. J Am Geriatr Soc 1989;37:730-4.
24. Hachinski VC, Illigg L, Duboulay GH, McAllister VL, Marshall J, Ross Russel RW, et al. Cerebral blood flow in dementia. Arch Neurol 1975;32:632-7.
25. Guy W, editor. ECDEU assessment manual for psychopharmacology. Rockville (MD): US Department of Health, Education and Welfare; 1976.
26. Honigfeld G, Gillis R, Klett CJ. Nurses Observation Scale for Inpatient Evaluation. In Guy W, editor. ECDEU assessment manual for psychopharmacology. Rockville (MD): US Department of Health, Education and Welfare; 1976.
27. Shulman KI, Shedletsky R, Silver IL. The challenge of time: clock-drawing and cognitive function in the elderly. Int J Geriatr Psychiatry 1986;1:135-40.
28. Sternbarg S. High speed scanning in human memory. Science 1966;153:652-4.
29. Sternberg S. Memory scanning: new findings and current controversies. Q J Exp Psychol 1975;27:1-32.
30. Folstein MF, Folstein SE, Mchugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
31. Alda M, Filip V. Strukturovaná skála nezdoucích úcinku psychofarmk. In: Filip V, David I, Jirák R, Posmurová M. Prakticky manual psychiatrickych posuzovacích stupnic. Zprávy 1985;68:47-54.
32. Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J Neurol Sci 1970;11:205-42.
33. Tomlinson BF, Henderson G. Some quantitative cerebral findings in normal and demented old people. In: Terry RD, Gershon S, editors. Neurobiology of aging, vol. 3. New York: Raven Press; 1976, p. 47-59.
34. Goldman-Rakic PS, Lidow MS, Smiley JF, Williams MS. The anatomy of dopamine in monkey and human prefrontal cortex. J Neural Transm Suppl 1992;36:163-77.
35. Funahashi S, Bruce CJ, Goldman-Rakic PS. Dorsolateral pre-frontal lesions and oculomotor delayed response performance: evidence for mnemonic "scotomas." J Neurosci 1993;13(4): 1479-97.